• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Have the Charts of Pfizer Changed Monday Morning?

Let's take a look amid the announcement that Pfizer's Covid-19 vaccine has progressed further.
By BRUCE KAMICH
Nov 09, 2020 | 08:49 AM EST
Stocks quotes in this article: PFE

We last looked at Pfizer (PFE) on October 26 and wrote that, "Ahead of Pfizer's earnings... the charts suggest that investors are not positioned for an upside move." We noted that PFE showed a Point and Figure target of $42.

Well, we now have earnings behind us and Monday's announcement that Pfizer's Covid-19 vaccine has progressed further.

Let's check the charts again.

In the updated daily bar chart of PFE, below, we can see the price action before Monday's morning's announcement. Prices weakened into early November. The slopes of the moving averages were negative and the On-Balance-Volume (OBV) line was at a new low. The Moving Average Convergence Divergence (MACD) oscillator is just below the zero line.  

In the weekly bar chart of PFE, below, we can see a mildly positive picture. Prices are above the 40-week moving average line but this slope is negative.

The weekly OBV line shows improvement from September and the MACD oscillator is above the zero line and the two moving averages that make up the indicator are on top of each other.

In this Point and Figure chart of PFE, below, we used daily close-only price data with a traditional even-dollar scaling. Here the software is projecting a potential price target of $50.


Bottom-line strategy: PFE is going to gap higher Monday morning. Fundamental and technical analysts will all be writing updates. If you have a long position in PFE from lower levels -- great. I would recommend raising stops to $35. Resistance might be encountered above $42 but $50 is now the Point and Figure target.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Pharmaceuticals | Coronavirus

More from Stocks

This Bull Market Is Not an Equal Opportunity Employer

James "Rev Shark" DePorre
Apr 15, 2021 4:32 PM EDT

We're seeing great action for major funds that are holding big-cap names, but downright lousy action for individual traders.

Jim Cramer: We've Got a Boom ... and a Bust

Jim Cramer
Apr 15, 2021 3:36 PM EDT

Let's look at this impossible move on the market -- and why health care could be coming off life support.

Make a Post-It: This Dividend King Will Stick Around

Bob Ciura
Apr 15, 2021 3:05 PM EDT

3M is a high-quality stock that sells more than 60,000 products in more than 200 countries.

The Technical Condition of Amarin Corp. Remains Weak

Bruce Kamich
Apr 15, 2021 2:45 PM EDT

Let's review the charts and indicators.

A Trade for a 'King'

Mark Sebastian
Apr 15, 2021 2:27 PM EDT

Let's look at Draftkings as it approaches earnings.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:42 PM EDT PAUL PRICE

    Wednesday on Real Money Pro

    Make this stock a 'part' of your portfolio.
  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login